Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq
@ASCO
Our incoming chief fellow Dr. Tanmayi Pai is moderating a work life balance discussion for all trainees and early career faculty πππ #ASCO24@ASCO@MayoClinic@MayoCancerCare
Our very best program director Dr. @RManochakian is moderating a very hot topic of managing locally advanced NSCLC! πππ #ASCO24@ASCO@MayoClinic
Great presentation and discussion of PERLA trial by Drs. Peters and Reguart. Exciting numerical OS advantage of dostarlimab+CT over pembrolizumab+CT 19.4 v 15.9m. However, was pembro+CT underperforming comparing to KN189, especially in PD-L1>50% subgroup? @myESMO#ESMO23
At #ASCO23 Dr. @RManochakian, thoracic oncologist & vice chair for education at @MayoClinic in Florida, presented in an education session on integrating #LearningScience principles and how to "ACE" teaching through oncology presentations to make them memorable and effective.
π₯π¨@OncoAlert#ASCO23 NEGATIVE results of #Keynote789 trial:
Platinum + Pem +/- Pembro for TKI-resistant #EGFR mutant #NSCLC
βPFS HR 0.8, P=0.0122
mPFS: 5.6 vs 5.5 mths
βOS HR 0.84, P=0.0362
mOS: 15.9 vs 14.7 mths
After TKI , adding Pembro to chemo DOES NOT improve OS
#ASCO23 π«WU-KONG6: Phase 2 Sunvozertinib for EGFR Exon20Ins
1β£ORR 60.8% (48.5% in pts w/ brain mets)
2β£ORR consistent across loop location
3β£Median DOR not reached after median f/u at 7.1 mos for responders
β A new promising drug for EGFR Exon20Ins
Great work by @LovaSunMD@CharuAggarwalMD published during #ASCO23 . Answered a clinical-relevant question that many practicing oncologists are waiting for. Congrats!
πin @CCR_AACR an analysis investigating the efficacy of Osi in pts with lung cancer harbouring *uncommon* EGFR exon 19 del mutβs
E746_A750del was associated with significantly prolonged mPFS with 1L Osi vs. L747_A750>P (21.3 vs. 11.7m; [HR] 0.52 ; p=0.043).
Understanding differences in Osi efficacy among EGFR ex19del subtypes could alter management of these pts in the future
https://t.co/OOhZBLEck4
Fresh and hot updates at #ELCC23 on CM816, showing persistent benefits of neoadjuvant Nivo+chemo in resectable NSCLC. Interestingly, the benefits seem more in preventing distal metastasis rather than local recurrence. What could be a possible explanation?@nicogirardcurie@myESMO
Although itβs cold and rainy in Copenhagen, feeling the heat in #ELCC23 lung cancer conference. A big discrepancy in audiences in choosing 1st line therapy for EGFR ex20ins LUAD. Speaker Dr Girard chose chemo+bev to avoid immunotherapy. @myESMO@IASLC